0001209191-23-049809.txt : 20230918 0001209191-23-049809.hdr.sgml : 20230918 20230918181351 ACCESSION NUMBER: 0001209191-23-049809 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230914 FILED AS OF DATE: 20230918 DATE AS OF CHANGE: 20230918 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LOUMEAU ERIC J CENTRAL INDEX KEY: 0001239648 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37985 FILM NUMBER: 231262075 MAIL ADDRESS: STREET 1: C/O HOLLIS-EDEN PHARMACEUTICALS STREET 2: 4435 EASTGATE MALL STE.400 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ANAPTYSBIO, INC CENTRAL INDEX KEY: 0001370053 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 203828755 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10770 WATERIDGE CIRCLE, SUITE 210 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-362-6295 MAIL ADDRESS: STREET 1: 10770 WATERIDGE CIRCLE, SUITE 210 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: ANAPTYSBIO INC DATE OF NAME CHANGE: 20080828 FORMER COMPANY: FORMER CONFORMED NAME: ANAPTYS BIOSCIENCES INC DATE OF NAME CHANGE: 20060724 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-09-14 0 0001370053 ANAPTYSBIO, INC ANAB 0001239648 LOUMEAU ERIC J C/O ANAPTYSBIO, INC. 10770 WATERIDGE CIRCLE, SUITE 210 SAN DIEGO CA 92121 0 1 0 0 Chief Legal Officer 0 Common Stock 2023-09-14 4 M 0 6000 A 6882 D Common Stock 2023-09-14 4 S 0 2105 19.48 D 4777 D Common Stock 2023-09-18 4 S 0 3895 19.3151 D 882 D Restricted Stock Unit 2023-09-14 4 M 0 6000 0.00 D Common Stock 6000 6000 D Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Reflects the acquisition of 882 shares acquired under the Company's ESPP. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.135 to $19.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. 50% of the total restricted stock units vest on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. /s/ Eric Loumeau 2023-09-18